Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of combining paclitaxel and bryostatin 1 in
treating patients who have metastatic prostate cancer that has not responded to hormone
therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI) University of Maryland, Baltimore